FORM 8.3
PUBLIC DEALING DISCLOSURE BY
A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
Rule 8.3 of the Takeover Code (the "Code")
1. KEY
INFORMATION
(a) Full name of Invesco Ltd.
discloser:
(b) Owner or
controller of
interests and
short
positions
disclosed, if
different
from 1(a):
The naming of
nominee or
vehicle
companies is
insufficient.
For a trust,
the
trustee(s),
settlor and
beneficiaries
must be
named.
(c) Name of Advanced Medical
offeror/offere Solutions Group PLC
e in relation
to whose
relevant
securities
this form
relates:
Use a
separate form
for each
offeror/offere
e
(d) If an exempt
fund manager
connected
with an
offeror/offere
e, state this
and specify
identity of
offeror/offere
e:
(e) Date position 28.08.2026
held/dealing
undertaken:
For an
opening
position
disclosure,
state the
latest
practicable
date prior to
the
disclosure
(f) In addition N/A
to the
company in
1(c) above,
is the
discloser
making
disclosures
in respect of
any other
party to the
offer?
If it is a
cash offer or
possible cash
offer, state
"N/A"
2. POSITIONS OF
THE PERSON
MAKING THE
DISCLOSURE
If there are
positions or
rights to
subscribe to
disclose in
more than one
class of
relevant
securities of
the offeror or
offeree named
in 1(c), copy
table 2(a) or
(b) (as
appropriate)
for each
additional
class of
relevant
security.
(a) Interests and
short
positions in
the relevant
securities of
the offeror or
offeree to
which the
disclosure
relates
following the
dealing (if
any)
Class of 5p ordinary, ISIN:
relevant GB0004536594, LEI:
security: 213800HJP6OWOSZI1L74
Interests Short
Positions
Number % Number
%
(1) Relevant 2,242,847 1.01
securities
owned and/or
controlled:
(2) Cash-settled
derivatives:
(3) Stock-settled
derivatives
(including
options) and
agreements to
purchase/sell:
Total 2,242,847 1.01
All interests
and all short
positions
should be
disclosed.
Details of any
open stock
-settled
derivative
positions
(including
traded
options), or
agreements to
purchase or
sell relevant
securities,
should be given
on a
Supplemental
Form 8 (Open
Positions).
(b) Rights to
subscribe for
new securities
(including
directors' and
other employee
options)
Class of
relevant
security in
relation to
which
subscription
right exists:
Details,
including
nature of the
rights
concerned and
relevant
percentages:
3. DEALINGS (IF
ANY) BY THE
PERSON MAKING
THE DISCLOSURE
Where there
have been
dealings in
more than one
class of
relevant
securities of
the offeror or
offeree named
in 1(c), copy
table 3(a),
(b), (c) or (d)
(as
appropriate)
for each
additional
class of
relevant
security dealt
in.
The currency of
all prices and
other monetary
amounts should
be stated.
(a) Purchases and
sales
Class of Purchase/sale Number of Price
per
relevant securities unit
security
5p ordinary Sale 284 2.82
GBP
GB0004536594
(b) Cash-settled
derivative
transactions
Class of Product Nature of Number of
Price
relevant description dealing reference
per
security e.g. CFD e.g. securities
unit
opening/clo
sing a
long/short
position,
increasing/
reducing a
long/short
position
(c) Stock-settled
derivative
transactions
(including
options)
(i) Writing,
selling,
purchasing or
varying
Class of Product Writing, Number of Exercise Type e.g.
Expiry date Option
relevant description purchasing, securities price per American,
money
security e.g. call selling, to which unit European etc.
paid/
option varying option
received
etc. relates
per unit
(ii) Exercise
Class of Product Exercising/ Number of
Exercise
relevant description exercised securities
price
security e.g. call against per
unit
option
(d) Other dealings
(including
subscribing
for new
securities)
Class of Nature of Details Price
per
relevant dealing e.g. unit
(if
security subscription,
applicable)
conversion
4. OTHER
INFORMATION
(a) Indemnity and
other dealing
arrangements
Details of any
indemnity or
option
arrangement, or
any agreement
or
understanding,
formal or
informal,
relating to
relevant
securities
which may be an
inducement to
deal or refrain
from dealing
entered into by
the person
making the
disclosure and
any party to
the offer or
any person
acting in
concert with a
party to the
offer:
Irrevocable
commitments and
letters of
intent should
not be
included. If
there are no
such
agreements,
arrangements or
understandings,
state "none"
None
(b) Agreements,
arrangements,
or
understandings
relating to
options or
derivatives
Details of any
agreement,
arrangement or
understanding,
formal or
informal,
between the
person making
the disclosure
and any other
person relating
to:
(i) the voting
rights of any
relevant
securities
under any
option; or
(ii) the voting
rights or
future
acquisition or
disposal of any
relevant
securities to
which any
derivative is
referenced:
If there are no
such
agreements,
arrangements or
understandings,
state "none"
None
Is a NO
Supplemental
Form 8 (Open
Positions)
attached?
Date of 01.09.2026
disclosure
Contact name Philippa
Holmes
Telephone +441491417447
number
Public disclosures under Rule 8 of the Code must be made to a Regulatory
Information Service.
The Panel's Market Surveillance Unit is available for consultation in relation
to the Code's disclosure requirements on +44 (0)20 7638 0129. The Code can be
viewed on the Panel's website at www.thetakeoverpanel.org.uk.
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/invesco-ltd-/r/invesco-ltd--form-8-3---advanced-medical-solutions-group-plc--public-dealing-disclosure,c4390360Invesco Ltd. - Invesco Ltd: Form 8.3 - Advanced Medical Solutions Group Plc; Public dealing disclosure
Summary by 6ix AI
Invesco Ltd. sold 284 ordinary shares of Advanced Medical Solutions Group PLC at 2.82 GBP each on August 28, 2026, in a public dealing disclosure made under Rule 8.3 of the UK Takeover Code, which requires holders of 1% or more of a company involved in a takeover offer period to report their dealings.
Key details
- After the sale, Invesco Ltd. owned or controlled 2,242,847 of Advanced Medical Solutions Group PLC's 5p ordinary shares, or 1.01%, with no short positions disclosed.
- Invesco Ltd. reported no cash-settled or stock-settled derivative positions and no indemnity, option or voting arrangements relating to the shares.
- The disclosure is dated September 1, 2026.
6ix AI wrote this summary from the release below and checked it against the release.
Story so far
Earlier from Invesco
- Invesco Announces Retirement of Andrew Lo and Appointment of Marty Franc as Senior Managing Director and Head of Asia Pacific
- Invesco Advances Global Solutions & Custom Strategies Platform
- Invesco Ltd. Announces July 31, 2026 Assets Under Management
- Second Quarter 2026 Press Release
- Invesco Reports Results for the Three Months Ended June 30, 2026
Later from Invesco
- Invesco Ltd. Announces August 31, 2026 Assets Under Management
- Invesco Defined Contribution Survey Reveals Plan Participants are Open to Private Markets and AI Alongside Greater Education and Control
- The Invesco QQQ Innovation Suite Expands with the Launch of Invesco Nasdaq International Innovators 100 ETF (QQI)
- Invesco Ltd. to Announce Third Quarter 2026 Results
- Invesco Ltd. - Invesco Ltd: Form 8.3 - Prologis Inc; Public dealing disclosure
Follow Invesco into a list and get an email when it puts out news.
Follow Invesco